Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | PREP | P48147 | 3/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | KAT6A | Q92794 | 2/20 | 0.36 |
| ▸ | KAT8 | Q9H7Z6 | 2/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | JAK1 | P23458 | 1/20 | 0.34 |
| ▸ | TYK2 | P29597 | 1/20 | 0.34 |
| ▸ | JAK3 | P52333 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15085021 | 0.88 | CHRM2 (0.41) | CHRM2CHRM1CHRM3PREPGPR119 | |
| SCHEMBL1723133 | 0.88 | CHRM2 (0.41) | CHRM2CHRM1CHRM3HDAC1PREP | |
| SCHEMBL1722273 | 0.83 | CHRM2 (0.41) | CHRM2CHRM1CHRM3HDAC1PREP | |
| SCHEMBL16772710 | 0.83 | CHRM2 (0.38) | CHRM2CHRM1CHRM3GPR119KAT6A | |
| SCHEMBL16273432 | 0.82 | CHRNB2 (0.40) | CHRM2CHRM1CHRM3 | |
| SCHEMBL669989 | 0.82 | CHRM2 (0.44) | CHRM2CHRM1CHRM3HDAC1PREP | |
| SCHEMBL15085032 | 0.82 | USP30 (0.38) | CHRM2CHRM1CHRM3PREPGPR119 | |
| SCHEMBL10138669 | 0.81 | CHRM2 (0.36) | CHRM2CHRM1CHRM3GPR119ADORA2A | |
| SCHEMBL15085033 | 0.81 | CHRNB2 (0.49) | — | |
| SCHEMBL15085023 | 0.81 | CHRNB2 (0.51) | GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2494975-A1 | Compounds and methods for promoting smoking cessation | Research Triangle Institute (US) | 2012-09-05 | — | — | EP | disclosed |
| EP-2404923-A1 | 7-azabicyclo[2.2.1]heptane derivatives useful for promoting smoking cessation | RESEARCH TRIANGLE INSTITUTE (US) | 2012-01-11 | — | — | EP | disclosed |
| US-20090318490-A1 | COMPOUNDS AND METHODS FOR PROMOTING SMOKING CESSATION | RESEARCH TRIANGLE INSITUTE (US) | 2009-12-24 | — | — | US | disclosed |
| US-7615567-B2 | Compounds and methods for promoting smoking cessation | RESEARCH TRIANGLE INSTITUTE (US) | 2009-11-10 | — | — | US | disclosed |
| US-20060069111-A1 | Compounds and methods for promoting smoking cessation | RESEARCH TRIANGLE INSITUTE (US) | 2006-03-30 | — | — | US | disclosed |
| EP-1351684-A4 | COMPOUNDS AND METHODS FOR PROMOTING SMOKING CESSATION | RES TRIANGLE INST (US) | 2005-01-19 | — | — | EP | disclosed |
| EP-1351684-A2 | COMPOUNDS AND METHODS FOR PROMOTING SMOKING CESSATION | Research Triangle Institute (US) | 2003-10-15 | — | — | EP | disclosed |
| US-20030176434-A1 | Compounds and methods for promoting smoking cessation | RESEARCH TRIANGLE INSITUTE | 2003-09-18 | — | — | US | disclosed |
| US-6538010-B1 | Compounds may be used to treat a variety of other conditions and disease states and reagents for preventing smoking addiction. The present invention also relates to methods and reagents for treating nicotine addiction. | RESEARCH TRIANGLE INSTITUTE | 2003-03-25 | — | — | US | disclosed |
| WO-2002037927-A2 | COMPOUNDS AND METHODS FOR PROMOTING SMOKING CESSATION | RESEARCH TRIANGLE INSTITUTE (US) | 2002-05-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069111-A1 | Compounds and methods for promoting smoking cessation | BHMT2, CBS, NNMT | CHRM2 420/4885CHRM1 711/4885CHRM3 522/4885 |
| US-20090318490-A1 | COMPOUNDS AND METHODS FOR PROMOTING SMOKING CESSATION | BHMT2, CBS, NNMT | CHRM2 420/4885CHRM1 711/4885CHRM3 522/4885 |
| US-20030176434-A1 | Compounds and methods for promoting smoking cessation | BHMT2, CBS, NNMT | CHRM2 420/4885CHRM1 711/4885CHRM3 522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.